Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 10Melanoma 9Neoplasm Metastasis 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Histiocytoma, Malignant Fibrous 2Glioblastoma 2Carcinoma, Merkel Cell 2Carcinoma, Endometrioid 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Uveal Melanoma 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

Gemcitabine 29pembrolizumab 20Cisplatin 20Magnetic Resonance Spectroscopy 17Specimen Handling 16Mitomycin 10enfortumab vedotin 9durvalumab 9Cystoscopy 9avelumab 8Nivolumab 8Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 6atezolizumab 5Transurethral Resection of Bladder 5Radiotherapy 5Mitozytrex 5Docetaxel 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Platinum 4Immunoglobulin G 4Disulfides 41,2-diaminocyclohexaneplatinum II citrate 4disitamab vedotin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × CTLA-4 Antigen × 90 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡